CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


HP:0002515: Waddling gaitHPO

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug738 Delivery of iStride™ device gait treatment using telemedicine Wiki 1.00

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D020233 Gait Disorders, Neurologic NIH 1.00
D009422 Nervous System Diseases NIH 0.58

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Treatment of Hemiparetic Gait Impairments Using Telehealth With the Moterum iStride Solution™

The objective of this research is to investigate the feasibility of delivering gait treatment using the Moterum iStride Solution™ to individuals with hemiparetic gait impairments using a telemedicine modality, the Moterum Digital Platform.

NCT04434313 Telemedicine Gait, Hemiplegic Gait Disorders, Neurologic Stroke Orthotic Devices Gait Analysis Device: Delivery of iStride™ device gait treatment using telemedicine
MeSH:Gait Disorders, Neurologic Nervous System Diseases
HPO:Scissor gait Shuffling gait Spastic gait Steppage gait Unsteady gait Waddling gait

Primary Outcomes

Description: The described delivery method includes using remote physical therapist treatment oversight and physical supervision of treatment activities by trained caregivers. Due to the inclusion criteria, patients already have some risk of falls and need for assistance while walking. The caregivers will record assistance levels provided during treatment. Any adverse events will be immediately reported and reviewed. The remote physical therapists will regularly review assistance levels to ensure the participant is requiring an appropriate level of assistance. The feasibility of safely delivering treatment will be assessed by two measures: (a) the daily safety rate, defined as the percentage of days an adverse event occurred out of the total number of treatment days, and (2) assistance required and adverse events experienced for each participant, compared to the group, and compared to our prior research.

Measure: Feasibility of safely implementing the treatment protocol

Time: Determined at the end of the 12-session treatment period (approximately 4 weeks after beginning the treatment).

Description: The achievability of this treatment delivery method will be assessed by measuring participant compliance to the protocol tasks. These tasks include scheduled treatment sessions, functional and psychosocial outcome measures, and sensor-based activities. Achievability will be defined as the percentage of completed protocol activities out of the total scheduled activities.

Measure: Achievability of telemedicine delivery protocol

Time: Determined within one week after the final follow-up assessment (12-month follow-up) is completed. The 12-month follow-up assessment will occur 12-months after completion of the 4-week treatment period.

Secondary Outcomes

Description: To enroll patients via telemedicine, the eligibility criteria will be assessed with an additional video gait review performed by physical therapists. The feasibility of screening patients at a distance will be assessed by measuring screening performance, defined as the percentage of enrolled subjects who are removed from the study after later being deemed ineligible (for example, gait is not asymmetric or hemiparetic but appeared so on video, or patient cannot walk independently, etc.) out of all enrolled subjects.

Measure: Feasibility of screening criteria

Time: Determined at the end of the 12-session treatment period (approximately 4 weeks after beginning the treatment).

Description: Participant and caregiver feedback will be necessary to determine preferences and sentiments regarding the delivery method including technology management, training procedures, protocol activities, adequacy of caregiver and therapist support, device benefit, and overall satisfaction with procedures. Feedback will be gathered through a questionnaire using five-point Likert scales and open-ended questions. Questionnaires will be provided after completion of outcome measures at the final, 12-month follow-up assessment. Acceptability will be determined through percentage of positive responses out of the total questionnaire items.

Measure: Stakeholder Acceptability

Time: Determined within one week after the final follow-up assessment (12-month follow-up) is completed. The 12-month follow-up assessment will occur 12-months after completion of the 4-week treatment period.


HPO Nodes